Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cabozantinib-s-malate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 30 for your search:
Start Over
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-401, NCT01896479
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-309, NCT01908426
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120204, 12-C-0204, NCT01683994
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-240, NCT01866293
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-208, NCT01441947
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-274, NCT01466036
Cabozantinib in Advanced Solid Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-091, NCT01588821
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-0252, NCI-2014-00934, NCT01630590
Cabozantinib for Advanced Urothelial Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120205, 12-C-0205, NCT01688999
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130044, 13-C-0044, NCT01755195
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00554, 2012C0101, RU241210I, OSU 12154, 9312, N01CM00039, N01CM00070, N01CM00071, N01CM00099, P30CA016058, NCT01811212
A Study of XL184 (Cabozantinib) in Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PHL-086 / NCI 9322, NCT01815151
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: XL184-IST20, NCT01834651
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62113-55115, 2013-000762-11, UC1306, NCT01979393
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-490, NCT02036476
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 28313, NCT02041260
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: XL184-IST14, NCT02101736
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13-182, NCT02132598
Ph II CABOGIST in GIST
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1317, 2014-000501-13, NCT02216578
Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 and over
Sponsor: NCI
Protocol IDs: NCI-2014-01927, CABONE, 9620, NCT02243605
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-359, NCT02260531
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-02411, NRG GY001, U10CA180868, NCT02315430
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-005, NCT01582295
Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00740, AMC-087, U01CA121947, NCT01822522
Start Over